metastatic hormone-sensitive prostate cancer
Conditions
Interventions
None listed
Sponsors
Sapporo Medical University School of Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC). 2)Patients must be 20 years of age or older at the time of consent. 3)Patients capable of oral intake. 4)Patients receiving drug therapy for mHSPC that does not include chemotherapy. 5)Cases for which written consent has been obtained from the patient to participate in this study.
Exclusion criteria
Exclusion criteria: 1) Individuals without a histological diagnosis of prostate cancer. 2) Individuals with a history of malignant tumors other than prostate cancer within the past three years. 3) Individuals with severe, hospitalization-requiring, uncontrolled complications other than malignant tumors. 4) Individuals with convulsive disorders requiring anticonvulsant therapy, except those who are clinically stable or seizure-free. 5) Patients with severe hepatic impairment Patients with a history of hypersensitivity to any component of mHSPC therapy drugs. Patients lacking the ability or willingness to cooperate with the procedures of this study. 8) Patients deemed unsuitable for this study by the investigator. Example: Patients participating in another clinical study (interventional study).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to CRPC-progression | — |
Countries
Japan
Contacts
Public ContactKohei Hashimoto
Sapporo Medical University School of Medicine Department of Urology
Outcome results
None listed